Homepage Top Section1

As per the agreement, US-based Gilead will buy worldwide rights, with the exception of South Korea, to develop and commercialize novel small molecules against two undisclosed targets. In

Alopecia areata is a chronic autoimmune skin disease, which makes hair loss on the scalp, face and body.  At present, there are no approved therapies for this autoimmune

The dug will be produced at the group’s Topical manufacturing facility at Ahmedabad in Gujarat, India. This combination medication, according to the pharma company, is used to treat

Scars caused by eye infection or trauma convert the usually transparent cornea into an opaque state, thereby leading to blurred vision or complete blindness. Compared with existing standard

The SOLO-3 late-stage trial, which evaluated the efficacy and safety of Lynparza, featured 266 patients whose ovarian cancer relapsed following two or more lines of treatment. Patients were

UPSA is a French pharmaceutical manufacturer, which develops and produces pharmaceutical drugs and supplements for everyday ailments. The company provides various products in therapeutic areas, including pain, cough

VE303 is claimed to be the first drug featuring a rationally-defined bacterial consortium to advance to phase 2 study. The earlier announced phase 1a/1b study showed rapid, durable,

The deal will allow AMAG to acquire global rights of ciraparantag, a next generation anticoagulant reversal agent, from Perosphere. As per terms of the deal, Perosphere equityholders will

Circassia has issued a notice of option exercise to AstraZeneca related to US commercial rights of Tudorza. The company intends to complete the option exercise by the end